Reports Q1 revenue $77.7M, consensus $76.98M. “Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
- Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies
- Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
- Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal
- Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR